Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder
Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment
Share
Why It Matters
Clearmind Medicine found enough people to test its new alcohol treatment drug. When a medicine company reaches these early milestones, it shows the research is moving forward as planned.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.